{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269470","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.105751+00:00","generated_at":"2026-05-16T23:46:40.807989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M","bullets":["89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.","Introduced trispecific molecules APVO451 and APVO452 for solid tumors, expanding CD3 T-cell engager portfolio to five candidates.","Raised $18.7M net in Q3 and additional $4.1M in October; proforma cash $25.2M extends runway into 4Q26.","Q3 net loss $7.5M ($2.23 per share) vs $5.1M ($357.86 per share) in Q3 2024; R&D spend $4.0M, G&A $3.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269470","json":"https://secwatch.observer/filing/0001193125-25-269470.json","markdown":"https://secwatch.observer/filing/0001193125-25-269470.md","text":"https://secwatch.observer/filing/0001193125-25-269470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/0001193125-25-269470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/apvo-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:46:40.807989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}